Non-Hodgkin Lymphoma Clinical Trials

218 recruitingLast updated: June 6, 2026

There are 218 actively recruiting non-hodgkin lymphoma clinical trials across 47 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Non-Hodgkin Lymphoma Trials at a Glance

218 actively recruiting trials for non-hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 1 with 112 trials, with the heaviest enrollment activity in Houston, New York, and Atlanta. Lead sponsors running non-hodgkin lymphoma studies include City of Hope Medical Center, Baylor College of Medicine, and Mayo Clinic.

Browse non-hodgkin lymphoma trials by phase

Treatments under study

About Non-Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for Non-Hodgkin Lymphoma? There are currently 105 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 218 trials

Recruiting
Phase 1Phase 2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaLymphoma+1 more
National Cancer Institute (NCI)155 enrolled1 locationNCT03223610
Recruiting
Phase 1

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedMature T-Cell and NK-Cell Non-Hodgkin LymphomaFollicular Helper T-Cell Lymphoma+3 more
City of Hope Medical Center20 enrolled1 locationNCT07278856
Recruiting
Phase 2Phase 3

Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents

Mature B-cell Non-Hodgkin Lymphoma
Children's Cancer Group, China87 enrolled1 locationNCT07168980
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1Phase 2

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 2

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell LymphomaRefractory Transformed B-cell Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma Refractory+1 more
The Lymphoma Academic Research Organisation65 enrolled13 locationsNCT06271057
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 1Phase 2

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Mature B-cell Non-Hodgkin Lymphoma
Hoffmann-La Roche65 enrolled30 locationsNCT05533775
Recruiting
Phase 2

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma
Genmab496 enrolled76 locationsNCT05283720
Recruiting
Phase 1

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Non-Hodgkin LymphomaPlasmablastic LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI)25 enrolled1 locationNCT05389423
Recruiting
Phase 1

A Phase I Study of JLM019 Injection

Hodgkin LymphomaNon-Hodgkin LymphomaAdvanced Solid Tumor (Phase 1)
Jecho Biopharmaceuticals Co., Ltd.115 enrolled1 locationNCT07623850
Recruiting
Phase 1

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+15 more
Sumithira Vasu54 enrolled2 locationsNCT05418088
Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Malignant Brain NeoplasmMalignant Solid NeoplasmMalignant Testicular Neoplasm+97 more
University of Southern California250 enrolled2 locationsNCT07259304
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1Phase 2

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535
Recruiting

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Non-Hodgkin LymphomaMultiple Myeloma
Memorial Sloan Kettering Cancer Center20 enrolled8 locationsNCT07249528
Recruiting
Phase 2

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

High-grade B-cell LymphomaLymphoma, Non-HodgkinRefractory Diffuse Large B-Cell Lymphoma+2 more
Abramson Cancer Center at Penn Medicine31 enrolled1 locationNCT06458439
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Not Applicable

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Multiple Myeloma+1 more
Ohio State University Comprehensive Cancer Center90 enrolled1 locationNCT07609030